OShares US Small-Cap Quality Div ETF

Wells Fargo Raises Texas Roadhouse Stock Rating to Outperform with a $195 Price Target

Royalty Pharma Secures MYQORZO Royalty Rights

Wells Fargo Raises Texas Roadhouse to 'Overweight', Raises PT to $195

Western Union Plans to Launch Cross-border Remittance Service with Deutsche Post

Royalty Pharma Acquires Two Therapy Licenses from Nuvalent

TD Cowen Analyst Maintains Buy Rating for Royalty Pharma

Radian Group Inc. Receives Regulatory Approval for Acquisition of Inigo Limited

Royalty Pharma's Executive VP Sells Company Stocks

Western Union Launches Stable Card to Aid Users in High-Inflation Countries

Western Union to Issue Stablecoin Prepaid Cards

Royalty Pharma insiders sold $4.375 million worth of shares

Morgan Stanley Analyst Maintains Sell Rating on Western Union

Donaldson released FY2026 Q1 earnings on December 4 During-Market (EST), actual revenue USD 935.4 M (forecast USD 922.94 M), actual EPS USD 0.97 (forecast USD 0.9066)

Donaldson Updates 2026 Fiscal Year Earnings Guidance

Denali Therapeutics and Royalty Pharma Reach $275 Million Financing Agreement

Royalty Pharma CFO sells company stocks

Norwegian bank invests $354 million in Lincoln Electric Holdings

Donaldson to release FY2026 Q1 earnings on December 4, 2025, pre-market EST; forecast revenue USD 922.94 M, EPS USD 0.9066

Royalty Pharma's EVP and CFO Terrance P. Coyne Sold Common Stock

George W. Lloyd sold 135,426 shares of Royalty Pharma

A SPAC III Acquisition

PicoCELA

Davis Commodities

Society Pass

ECD Automotive Design

Gauzy

Bristol-Myers Squibb Company

A SPAC III ACQUISITION CORP. COM NPV CL A (SUBS/RTS)02/01/2026

Paranovus ENT Tech

Cue BioPharma

TXRH

Jim Cramer believes Texas Roadhouse (TXRH) can reach $200 per share. Wells Fargo recently upgraded the stock to Overweight with a $195 price target.

Texas Roadhouse

Texas Roadhouse (TXRH) can touch $200, says Jim Cramer

Polianta Ltd purchased 9,200 shares of TD SYNNEX Corporation during the 3rd quarter, valued at approximately $1,506,000. Several other hedge funds also acquired or increased their stakes in TD SYNNEX. The company's stock opened at $153.10 on Friday with a market cap of $12.47 billion. TD SYNNEX reported strong earnings for the quarter, with a net margin of 1.27% and a return on equity of 12.13%. Analysts have given the stock a 'Moderate Buy' rating with a consensus target price of $169.18.

Market Beat

TD Synnex

Polianta Ltd Buys Shares of 9,200 TD SYNNEX Corporation $SNX

RBC Capital analyst David Paige maintained a Buy rating for TD SYNNEX Corporation, setting a price target of $180.00. Paige is a 3-star analyst with a 16.6% average return and an 85.71% success rate. The analyst consensus for TD SYNNEX is Strong Buy, with a price target consensus of $176.56.

Tip Ranks

RBC Capital Sticks to Its Buy Rating for TD SYNNEX Corporation (SNX)

RBC Capital's Logan Reich maintained a Hold rating on Texas Roadhouse with a $175 price target. Reich, who covers the Consumer Cyclical sector, has an average return of -8.8% and a 52.29% success rate. Stifel Nicolaus also rated it Hold, while Wells Fargo upgraded it to Buy on December 17.

Texas Roadhouse (TXRH) Receives a Hold from RBC Capital

RPRX

Marshall Urist, EVP at Royalty Pharma plc, reported the disposal of common shares of the company. This information was published via EDGAR by Royalty Pharma plc and is for informational purposes only, not financial advice.

Reuters

Royalty Pharma PLC - CL

EVP Marshall Urist Reports Disposal of Royalty Pharma plc Common Shares

Royalty Pharma announced its entitlement to royalties after FDA approval of MYQORZO for treating obstructive hypertrophic cardiomyopathy. They will receive 4.5% royalties on sales up to $5 billion and have $175 million funding available for Cytokinetics post-approval. Additionally, Royalty Pharma will receive 1.9x repayment on drawn funds over 10 years.

TradingView

Royalty Pharma Gains from MYQORZO FDA Approval

TD SYNNEX has launched its AI Game Plan workshop, part of the Destination AI framework, to help partners create 90-day AI execution roadmaps. The company's stock is trading at $154.13, with a 32% year-to-date return and a 99% five-year return. Despite strong returns, shares are undervalued with a fair value of $178.36. The company's growth in software and IT infrastructure is expanding its market and revenue streams. However, potential risks include demand fluctuations and margin pressures.

Simplywall

A look at TD SYNNEX’s valuation as it launches its new AI Game Plan workshop for partners

Texas Roadhouse shares rose 1.3% premarket after Wells Fargo upgraded the stock to "overweight" and increased the price target to $195 from $170. The brokerage views beef cost headwinds as cyclical and expects them to ease by the second half of 2026. Casual dining is anticipated to perform well in 2026, with margin recovery expected for Texas Roadhouse later in the year. Currently, 12 out of 31 analysts rate the stock as "buy" or higher, while 19 rate it "hold." The median price target is $188.

BUZZ-Texas Roadhouse up after Wells Fargo upgrades stock, hikes PT

Morgan Stanley's Erik Woodring maintains a Buy rating on TD SYNNEX Corporation with a $177 price target. Woodring, a 5-star analyst, has an average return of 11.8% and a 62.11% success rate. The analyst consensus suggests a Strong Buy rating for TD SYNNEX with a $176.56 average price target.

TD SYNNEX Corporation (SNX) Receives a Buy from Morgan Stanley

Sandy Lamm LLC, a shareholder of Royalty Pharma PLC, filed a Form 144 with the SEC to sell 160,000 shares on December 16, 2025. The sale is executed under a prearranged trading plan (10b5-1) through Merrill Lynch & Co Inc. Form 144 allows the sale of restricted stock within 90 days of filing.

Shareholder Sandy Lamm LLC Files To Sell 160,000 Of Royalty Pharma PLC [RPRX]

Royalty Pharma has acquired a royalty interest in Nuvalent's drugs, neladalkib and zidesamtinib, for up to $315 million. These drugs are next-generation tyrosine kinase inhibitors for treating non-small cell lung cancer. Neladalkib is in Phase 3 trials, while zidesamtinib is under FDA review. The acquisition includes a low-single digit royalty on global sales, expected to last until 2041-2042. Analysts project significant sales for both drugs by 2035.

StockTitan

Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million | RPRX Stock News

TPC RP EPA1 LLC, a shareholder of Royalty Pharma PLC, filed a Form 144 with the SEC to sell 3,750 shares on December 15, 2025, through Goldman Sachs & Co. This sale is executed under a prearranged trading plan (10b5-1). Filing Form 144 is a prerequisite for selling restricted securities, allowing the sale within 90 days of filing.

Shareholder TPC RP EPA1 LLC Files To Sell 3,750 Of Royalty Pharma PLC [RPRX]

Alliancebernstein L.P. increased its holdings in Texas Roadhouse, Inc. by 528.2% in Q2, owning 3,172,738 shares valued at $594.6 million. This significant investment highlights institutional interest in the restaurant operator. Texas Roadhouse's stock is trading at $167.36, with a market cap of $11.07 billion. The company reported Q3 earnings of $1.25 per share, slightly below estimates, and announced a quarterly dividend of $0.68. Recent insider sales were disclosed, and analysts have set new price targets for the stock.

AllianceBernstein

Alliancebernstein L.P. Boosts Stock Holdings in Texas Roadhouse, Inc. $TXRH